Incyte Corporation's JAK Inhibitor Demonstrates Marked Clinical Benefits in Phase IIa Rheumatoid Arthritis Study

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announced today the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus-associated kinase (JAK) inhibitor, in patients with rheumatoid arthritis (RA). Results from the first of four treatment groups, involving 12 treated and 4 placebo patients, demonstrated that the 15 mg twice-daily dose of INCB18424 was well tolerated and provided ACR20/50/70/90 response rates of 75%/50%/25%/17%, respectively, with responses seen as early as 1 week. These results, coupled with the ability of INCB18424 to block signaling from multiple inflammatory cytokines, suggest that INCB18424 has the potential to be more effective than currently available RA therapies, including the widely used injectable biologicals. These results were presented today in an oral presentation during the “Non Biological Treatment in RA” session at the European League Against Rheumatism (EULAR) 2008 Congress in Paris, France.

Back to news